NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle

 NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle

MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus


  • The study involves assessing of investigational vaccine mRNA-1273 against COVID-19 enrolling 45 patients with age of 18 to 55 years ~6wks. and the first patient has been dosed. Additionally, National Institute of Allergy and Infectious Diseases (NIAID) is funding the P-I trial
  • The study will be evaluating two doses of the vaccine (IM, 25mcg, 100/250 mcg) in the upper arm ~ for 28 days apart due to its safety, and the ability to induce immune response. Till Mar 15, 2020 WHO has reported 153,517 cases of COVID-19 and 5,735 deaths worldwide with confirmed 2,800 cases and 58 deaths in the US
  • mRNA-1273 is an investigational vaccine developed by NIAID scientists in collaboration with Moderna. Additionally, the adults in Seattle who are interested in joining the study needs to visit

Click here to read full press release/ article | Ref: NIH | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post